

About Scientific Reports

[Aims & scope](#)

[Editorial process](#)

[Editors](#)

[Editorial Values Statement](#)


About Scientific Reports

Why publish in *Scientific Reports*?

Scientific Reports is an open access journal publishing original research from across all areas of the natural sciences, psychology, medicine and engineering.

Global influence

We offer our authors a highly respected home for their research. *Scientific Reports* is the 5th most-cited journal in the world, with more than 696,000 citations in 2021*, and receives widespread attention in policy documents and the media.



*2021 Journal Citation Reports® Science Edition (Clarivate Analytics, 2022)

Expert peer review

Partnering with our extensive network of expert peer reviewers, our editorial team provides rigorous, objective and constructive peer review, and will support you throughout the publication process. *Scientific Reports* is led by the same ethical and editorial policy guidelines

[About Scientific Reports](#)

[Aims & scope](#)

[Editorial process](#)

[Editors](#)

[Editorial Values Statement](#)

Aims & scope

We publish original research from all areas of the natural sciences, psychology, medicine and engineering. You can learn more about what we publish by browsing our specific scientific subject areas below or explore *Scientific Reports* by browsing all articles and collections.

Scientific Reports has a 2-year impact factor: 4.996 (2021), and is the 5th most-cited journal in the world, with more than 696,000 citations in 2021*.

*2021 Journal Citation Reports® Science Edition (Clarivate Analytics, 2022).

Engineering

Engineering covers all aspects of engineering, technology, and applied science. It plays a crucial role in the development of technologies to address some of the world's biggest challenges, helping to save lives and improve the way we live.

[Browse our articles](#) >

Physical sciences

Physical sciences are those academic disciplines that aim to uncover the underlying laws of nature — often written in the language of mathematics. It is a collective term for areas of study including astronomy, chemistry, materials science and physics.

[Browse our articles](#) >

Earth and environmental sciences

Earth and environmental sciences cover all aspects of Earth and planetary science and broadly encompass solid Earth processes, surface and atmospheric dynamics, Earth system history, climate and climate change, marine and freshwater systems, and ecology. It also considers the interactions between humans and these systems.

[Browse our articles](#) >

Biological sciences

Biological sciences encompass all the divisions of natural sciences examining various aspects of vital processes. The concept includes anatomy, physiology, cell biology, biochemistry and biophysics, and covers all organisms from microorganisms, animals to plants.

[Browse our articles](#) >

Health sciences

The health sciences study health, disease and healthcare. This field of study aims to develop knowledge, interventions and technology for use in healthcare to improve the treatment of patients.

[Browse our articles](#) >

Explore *Scientific Reports*

- [Browse all articles](#) >
- [Browse collections](#) >

[Browse our articles >](#)

Biological sciences

Biological sciences encompass all the divisions of natural sciences examining various aspects of vital processes. The concept includes anatomy, physiology, cell biology, biochemistry and biophysics, and covers all organisms from microorganisms, animals to plants.

[Browse our articles >](#)

Health sciences

The health sciences study health, disease and healthcare. This field of study aims to develop knowledge, interventions and technology for use in healthcare to improve the treatment of patients.

[About Scientific Reports](#)[Aims & scope](#)[Editorial process](#)[Editors](#)[Editorial Values Statement](#)

Editors

Our Editors

Scientific Reports is run by a team of experienced editors who are experts in their fields. From our Editorial Board Members and Senior Editorial Board to our in-house Editors, we work together to ensure that your research is expertly handled and that we consider it to be technically sound, scientifically valid, and ultimately suitable for publication.

- [In-house Editors](#) led by Chief Editor Dr Rafal Marszalek
- [Senior Editorial Board](#)
- [Editorial Board Members](#)
 - [Biology](#)
 - [Medicine](#)
 - [Physics](#)
 - [Chemistry](#)
 - [Materials](#)
 - [Earth & Environment](#)
 - [Engineering](#)
 - [Registered Reports](#)

In-house Editors

Chief Editor: Rafal Marszalek

Rafal's background is analytical and biological chemistry. He did his PhD and postdoctoral research in single-cell proteomics at Imperial College London, UK. He was an editor at *Genome Biology* for four years before joining *Scientific Reports* in August 2016.



Deputy Editor: Elizabeth Mann

Elizabeth has a background in pharmacology and completed her PhD in neuropharmacology at King's College London, UK. She joined *Scientific Reports* in January 2019.

ORCID 0000-0003-2616-3193



Deputy Editor: Eve Rooks

Eve joined *Scientific Reports* in 2019, after working as an editor on the Royal Society of Chemistry's materials chemistry and engineering portfolio for 3 years. Prior to this she completed a PhD in Earth Sciences at the University of Cambridge, UK in igneous petrology and mantle geochemistry. Her interests lie in materials for energy applications and deep earth geochemistry.

ORCID 0000-0001-5083-5936



Deputy Editor: Akila Sridhar

Akila joined *Scientific Reports* in September 2022 after working for four years with BMC Series Journals as a Senior Editor. She has a PhD in Microbiology from University of Aberdeen, UK and worked as an EMBO postdoctoral Fellow at Instituto Gulbenkian de Ciência, Portugal. Over her eleven years in research, she worked on understanding telomere biology and has experience in cell, molecular and developmental biology.

ORCID 0000-0003-1459-5888



Senior Editor: João Leite

João has a background in biodiversity and population genetics from the University of Porto, Portugal. He joined *Scientific Reports* in 2021 after completing a PhD on the evolution of the dinosaur hand at the Natural History Museum and University College London. His interests include palaeontology, functional morphology, biomechanics, phylogenetics, ecology and biodiversity.



Senior Editor: Madushi Wanaguru

Madushi's background is in biochemistry and molecular biology. She joined *Scientific Reports* in 2019 after a PhD at the Wellcome Trust Sanger Institute in Cambridge, UK and post-doctoral work at the Francis Crick Institute in London, UK.



ORCID 0000-0002-9656-2

Associate Editor: Will Bultitude

Will joined *Scientific Reports* in November 2022 after completing a post-doctoral position at UCL investigating the genetics of clathrin-mediated membrane trafficking. He also has a background in immunology and transplantation genetics following his PhD at Anthony Nolan Research Institute.



ORCID 0000-0003-2728-4237

Associate Editor: Silvia Butera

Silvia joined *Scientific Reports* in March 2021, after being a Research Fellow at the University of Sussex for 5 years. She obtained her PhD in Physics at Heriot-Watt University, UK; her research was in semiconductor detector physics.



ORCID 0000-0002-5321-143X

Associate Editor: Betty Mousikou

Betty did a PhD in Cognitive Science at Macquarie University and then worked in academia for 10 years: she was a Marie-Curie Experienced Researcher at Bangor University, a British Academy Postdoctoral Fellow at Royal Holloway, University of London, and a Research Scientist at the Max Planck Institute for Human Development and the University of Göttingen. Before joining *Scientific Reports* in March 2023, Betty was an Associate Editor at the BMC Series.



Associate Editor: Claire Potter

Claire joined *Scientific Reports* in April 2021 after working at a small academic publishing company for 18 months. She obtained her PhD from Imperial College London, UK and undertook postdoctoral work at King's College London, UK. Her research was focused on vascular biology.



ORCID 0000-0002-6404-2301

Associate Editor: Martyna Stachaczyk

Martyna joined *Scientific Reports* in February 2023 after completing a postdoctoral fellowship at École Polytechnique Fédérale de Lausanne, where she developed novel, information theoretical metrics for assessing perceptual uncertainty in human and animal models of hallucinations. She completed her PhD in Bioengineering at Imperial College London in June 2022. Her interests include man-machine interfaces, cognitive neurotechnology, computational neuroscience, and bio-inspired engineering solutions.



ORCID 0000-0003-0164-7781

Associate Editor: Thomas Tischer

Thomas studied Biochemistry and completed his PhD in Germany. During this time, he worked with *Xenopus laevis* frogs to understand the regulation of the cell cycle. He joined the MRC Laboratory of Molecular Biology in Cambridge, UK as a postdoc where he started to work with mouse oocytes. This experience made him fall in love with microscopy and he subsequently decided to work on centrosome biology in human cells, focusing on protein interactions and ubiquitylation. Thomas joined *Scientific Reports* in October 2022.



ORCID 0000-0002-6845-2762

Associate Editor: Rachel Toth

Rachel joined *Scientific Reports* in December 2022 and is based in the Washington DC (USA) office. She completed a Ph.D. in Oncological Sciences at the University of Utah studying epigenetic misregulation in colorectal cancer, after which she studied the tumor microenvironment and drug resistance at the University of Arizona Cancer Center.



ORCID 0000-0001-8897-5045

Associate Editor: Inês Trindade

Inês obtained her PhD from Universidade Nova in Lisbon (Portugal), after which she worked as a postdoc at the Freie Universität Berlin and the Potsdam University (Germany). She has a background in epigenetics, plant development and plant environmental interactions. She joined *Scientific Reports* in May 2022 and is based in the Berlin office.



ORCID 0000-0002-5221-767X

Associate Editor: Biz Tumell

Biz's background is in evolutionary biology. They completed their PhD at Cornell University, with a focus on sexual selection, followed by three years of postdoctoral work at the Technische Universität Dresden, in Germany. Biz joined *Scientific Reports* in September 2021 and is based in the USA.



ORCID 0000-0002-1068-304X

Associate Editor: Chenyu Wang

Chenyu Wang joined *Scientific Reports* in 2022 after working as a postdoctoral fellow in Los Alamos National Lab for 4 years. He completed a Ph.D. in Materials Chemistry at SUNY-Binghamton, USA, focusing on leveraging crystal growth knowledge to tailor the structure/properties of nanomaterials. Chenyu



specializes in heterogeneous catalysis, material sciences, and energy-related applications. In particular, he finds fulfillment in interacting with researchers and providing quality author experience.

ORCID 0000-0001-8447-5086

Senior Editorial Board

Senior Editorial Board Members of *Scientific Reports* handle manuscripts in a broad range of topics within their general areas of expertise, in addition to advising on editorial board and journal development. The Senior Editorial Board is selected based on exceptional contributions to the journal.

Derek Abbott, University of Adelaide, Australia - Biological Physics

Angel Abuelo, Michigan State University, USA - Immunology

Golam Jalal Ahammed, Henan University of Science and Technology, China - Plants

Kristian Almstrup, Copenhagen University Hospital, Rigshospitalet, Denmark - Genetics

Monica Alves, University of Campinas, Brazil - Ophthalmology

Juan Anguita, CiC bioGUNE, Spain - Immunology

Editorial Board Members

The Editorial Board manages the peer review process and makes final decisions on whether papers should be accepted. To learn more about some of our Editorial Board Members and discover what inspires them, please visit our [Editorial Board highlights](#) page.

The Editorial Board comprises experts from all major fields within the clinical, biological, chemical, physical and earth sciences, to ensure that each submission is handled by a specialist with an active research career.

The Editorial Board is structured around the following categories:

- [Registered Reports](#)

BIOLOGY:

- [Ageing](#)
- [Biological Physics](#)
- [Biomedical Engineering](#)
- [Biotechnology](#)
- [Cancer](#)
- [Cell Biology](#)
- [Chemical Biology](#)
- [Drug Discovery](#)
- [Ecology & Evolution](#)
- [Food](#)
- [Genetics](#)
- [Human Behaviour](#)
- [Immunology](#)
- [Metabolism](#)
- [Microbiology](#)
- [Nanotechnology](#)
- [Neuroscience](#)

[nature](#) > [scientific reports](#) > [articles](#) > articleArticle | [Open Access](#) | [Published: 01 August 2022](#)

Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis

Dewi Susanti Atmaja, Yulistiani, Suharjono & Elida Zairina *Scientific Reports* **12**, Article number: 13189 (2022) | [Cite this article](#)2088 Accesses | 2 Citations | 2 Altmetric | [Metrics](#)

Abstract

Tools to accurately predict and detect adverse drug reactions (ADR) in elderly patients have not been developed. We aimed to identify and evaluate reports on tools that predict and detect ADR in elderly patients (≥ 60 years). In this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases were searched until January 2022 using key terms “elderly,” “adverse drug reaction,” and “detection instruments.” Eighteen studies met the inclusion criteria, and they examined assorted interventions: STOPP/START version 1/2 ($n = 10$), Beers Criteria 2012 or 2015 ($n = 4$), Systematic Tool to Reduce Inappropriate Prescribing (STRIP) ($n = 2$), Tool to Reduce Inappropriate Medications (TRIM) ($n = 1$), Medication Risk Score (MERIS) ($n = 1$), Computerized alert systems ($n = 1$), and Norwegian General Practice-Nursing Home criteria ($n = 1$). The interventions affected the number of potential prescription omissions (OR, 0.50 [0.37–0.69]; $p < 0.0001$; four studies). No apparent reduction in the number of drug interactions within 2 months (OR, 0.84 [0.70–1.02]; $p = 0.08$; two studies) and mortality (OR, 0.92 [0.76–1.12]; $p = 0.41$; three studies) was observed. In conclusion, there is no definitive and validated assessment tool for detecting and predicting ADR in elderly patients. Thus, more research on refining existing tools or developing new ones is warranted.

Download PDF 

Sections

Figures

References

[Abstract](#)[Introduction](#)[Results](#)[Discussion](#)[Limitations](#)[Conclusion](#)[Methods](#)[Data availability](#)[References](#)[Acknowledgements](#)[Funding](#)[Author information](#)[Ethics declarations](#)[Additional information](#)[Supplementary Information](#)[Rights and permissions](#)[About this article](#)



OPEN

Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis

Dewi Susanti Atmaja^{1,2}, Yulistiani³, Suharjono³ & Elida Zairina^{3,4,5}✉

Tools to accurately predict and detect adverse drug reactions (ADR) in elderly patients have not been developed. We aimed to identify and evaluate reports on tools that predict and detect ADR in elderly patients (≥ 60 years). In this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases were searched until January 2022 using key terms “elderly,” “adverse drug reaction,” and “detection instruments.” Eighteen studies met the inclusion criteria, and they examined assorted interventions: STOPP/START version 1/2 ($n = 10$), Beers Criteria 2012 or 2015 ($n = 4$), Systematic Tool to Reduce Inappropriate Prescribing (STRIP) ($n = 2$), Tool to Reduce Inappropriate Medications (TRIM) ($n = 1$), Medication Risk Score (MERIS) ($n = 1$), Computerized alert systems ($n = 1$), and Norwegian General Practice-Nursing Home criteria ($n = 1$). The interventions affected the number of potential prescription omissions (OR, 0.50 [0.37–0.69]; $p < 0.0001$; four studies). No apparent reduction in the number of drug interactions within 2 months (OR, 0.84 [0.70–1.02]; $p = 0.08$; two studies) and mortality (OR, 0.92 [0.76–1.12]; $p = 0.41$; three studies) was observed. In conclusion, there is no definitive and validated assessment tool for detecting and predicting ADR in elderly patients. Thus, more research on refining existing tools or developing new ones is warranted.

Adverse drug reactions (ADR) are the main focus of the pharmacovigilance system, which is related to medication safety. According to the European Medicines Agency (EMA), ADR is defined as “a response to a drug product that is noxious and unwanted”. The definition is currently extended to allowable drug use, including unwanted drug reactions from off-label effects, poisoning, and medication errors¹. Additionally, the US Food and Drug Administration defines ADRs as untoward medical events possibly caused by the use of drugs in humans, because there is a possibility that the drug causes adverse effects². Increased life expectancy has led to an increase in the elderly population, who are more vulnerable to developing ADR as long as they use medications. Various factors can cause ADR, including aging-induced changes in physiology, resulting in conditions such as geriatric syndrome, comorbidity, and disease complexity. The elderly need to take medicines for maintaining their health and quality of life. They usually follow various drug regimens, which leads to the potential for drug interactions that can lead to ADR³.

When patients take more drugs, it is complicated to review the overall drug use which causes medication errors, potentially harmful interactions, and drug toxicity that can lead to hospitalization. The majority of drugs cause hospitalizations because of their side effects, including anticoagulants, antiplatelets, NSAIDs, opioids, and antihypertensives⁴. Identification of ADR should be evaluated objectively using a probability scale. Clinical medication reviews can help clinical pharmacists assess symptoms from patient interviews⁵. Causality assessment instruments can assist in providing data that health workers require to ensure the safety of patients using medications. The Naranjo algorithm and the assessment criteria established by the WHO Uppsala Monitoring

¹Doctoral Program of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia. ²Department of Pharmacy, Faculty of Health, Universitas Sari Mulia, Banjarmasin, Indonesia. ³Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Jalan Dokter Ir. Haji Soekarno, Mulyorejo, Surabaya 60115, Jawa Timur, Indonesia. ⁴Innovative Pharmacy Practice and Integrated Outcome Research (INACORE) Group, Universitas Airlangga, Surabaya, Indonesia. ⁵Center for Patient Safety Research, Universitas Airlangga, Surabaya, Indonesia. ✉email: elida-z@ff.unair.ac.id

Centre are the most commonly used tools for determining the causality of ADR events. However, both assessment instruments have advantages and disadvantages, and the Naranjo scale instrument cannot be used to evaluate more complex cases such as polypharmacy and multimorbidity⁶.

Because the physiology of elderly individuals differs from that of other populations (adults), it is necessary to select appropriate instruments for predicting and detecting ADR in the elderly to reduce and prevent ADR⁶. ADR causality assessment can contribute to pharmacovigilance through the evaluation of the risk profile; it can indicate the benefit of drugs and provide an early warning of potential ADR events. Causality instruments combined with trigger tools and health-worker competency can yield better results in ADR detection. A systematic review published in 2020 found 5 studies (meeting the studies' inclusion criteria) that suggested the high prevalence of adverse drug events (ADE) and ADR in older patients with dementia. Only one study documented ADE and has variability in ADR methods and definitions. Furthermore, the results may not apply to other populations and settings because of a limited number of wards⁷. Another systematic review published in 2014 found 4 studies that developed and validated the ADR prediction model for use in patients over 65 years old. However, assessment of the quality of studies was challenging due to poor reporting in the studies included in the review⁸. Therefore, there are no models that can be used as prediction tools for ADR⁸. Hence, we conducted a systematic review to recognize and analyze literature on tools/methods that can accurately predict and detect ADR in elderly patients (≥ 60 years). We (1) identified primary research related to the use or development of an ADR prediction and/or detection instrument used in elderly patients (≥ 60 years) with morbidity and polypharmacy, and (2) assessed the effectiveness of each instrument for ADR prediction and/or detection used in elderly patients (≥ 60 years) for preventing and reducing ADR.

Results

General characteristics of the studies. Of 13480 studies initially identified, 977 studies were retrieved and fully reviewed. We excluded 959 studies for the reasons outlined in the flow chart, based on the PRISMA guidelines (Fig. 1). Eighteen studies met the specific inclusion criteria at the end of the election process. Figure 1 represents the steps of the search and selection process. The typical studies included in this systematic review are presented in Supplementary Table S1. The included articles were published from 2011 to 2021; eleven of these studies were conducted in Europe, four in North America, two in Asia, and one in the Middle East. Regarding the design, ten studies were randomized controlled trials (RCTs); four, cluster randomized controlled trials (cRCTs); and four, controlled clinical trials (CCTs).

Most studies were conducted in a hospital setting and, according to the inclusion criteria, in elderly patients (seven studies in the inpatient ward; one, acute internal medicine ward; one, acute admissions unit; one, medical ward; one, geriatric inpatient ward; and one, acute geriatric ward). Four studies were conducted in the clinic (three studies in primary care and one in a geriatric outpatient clinic). Two studies were conducted in homes for elderly individuals. The median or mean age of respondents is specified in most of the studies, with the age of the respondents ranging from 72.4⁹ to 86.7 years¹⁰; however, two of the reports did not indicate the median or mean age of the respondents¹¹, and one only specified the age of the respondents¹². The number of respondents included in each study varied from 63¹³ to 81,905¹⁴. Only one report did not present the number of respondents; however, it presented the total number of homes for a mean of 35–48 elderly residents¹¹. The study periods lasted up to 12 months.

Screening tools used in the intervention. All included studies utilized simple to complex intervention tools related to ADR topics. Most tools used for screening potentially inappropriate medications (PIM) are STOPP/START version 1 or 2 (10 studies), Beers Criteria 2012 or 2015 (4 studies), Systematic Tool to Reduce Inappropriate Prescribing (STRIP) (2 studies), TRIM (1 study), MERIS (1 study), Norwegian General Practice-Nursing Home criteria (1 study), and Computerized alert systems (1 study).

Risk of bias in included studies. Bias risk ranged from low to high across studies, with varying sources of bias. The risk of outcome bias was high in four studies, wherein the risk of randomization process bias was either high or cause for concern. The deviation from the intended intervention bias was a source of concern herein. The resulting risk bias was high in one study. Some of the included studies exhibited a low risk of bias (Fig. 2).

Primary outcomes. A number of predicted and prevented ADR or AE was announced in three studies. Two studies showed no significant increase in the prevalence of falls with the STOPP/START screening intervention¹⁵. Nevertheless, one study showed that the prevalence was less during the six-month monitoring period, in the exposure group (5.8% vs. 8.4%; $p = 0.332$)¹⁶. One study that utilized the STRIP intervention demonstrated no significant difference in the number of first preventable drug-related hospital admissions ($p = 0.49$; Hazard Ratio was 0.89 [0.63–1.25])¹⁷.

Overall, the intervention with STOPP/START or STRIP probably leads to no change in the number of predicted and prevented ADR or AE in elderly patients (moderate evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (–1).

A number of reductions in ADR or AE was reported in three studies. Two studies showed a significant difference in the number of discontinued medications or medications subjected to dose reduction. One study with pharmacist and physician intervention using CAS demonstrated a higher rate of drug discontinuation and dosage reduction in the intervention group versus the comparison group two days after the alert (+30.0%) and hospital repatriation (+20.8%) but no significant difference in the number of in-hospital deaths. However, the analysis showed an almost 4% dwindle in the intervention group versus the comparison group¹⁸. One study with pharmacist intervention showed that 18% more medicines were stopped or subjected to dose reduction in the




Figure 1. Flow diagram for study selection.

exposure group, considering the number of medications administered upon admission (comparison vs. exposure: median [IQR] was 0.32 [0.21–0.49] vs. 0.50 [0.42–0.63]; $p < 0.001$) and identified by the “Rationalization of Home Medication by an Adjusted STOPP in Older Patients” (RASP) List (comparison vs. intervention: median [IQR] was 1 [1, 2] vs. 2 [1–4]; $p = 0.003$)¹⁹. One study with STOPP/START screening exhibited a significant reduction in the mean number of falls in the exposure group within the monitoring period ($p = 0.006$); however, no significant reduction in the mean number of hospitalizations was observed in the exposure group ($p = 0.40$)¹⁵.

Overall, the CAS-based pharmacist–physician intervention, pharmacist intervention, and STOPP/START screening may lead to little or no effect in reducing ADR or AE in elderly patients (low evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (–1) and impreciseness because of low event numbers (–1).

A number of reductions in exposure to polypharmacy was observed in three studies and was significant in the exposure group. Two studies with STOPP/START screening intervention showed a 14.6% reduction in polypharmacy in the exposure group at discharge¹⁶ and a reduction in the mean number of medications in the exposure group throughout the monitoring period ($p < 0.001$) and in the comparison and exposure groups at the end of the study ($p < 0.001$), these results are from ($p < 0.001$)¹⁵. A study that utilized the PEPS model

ROBINS-I

First author, year	Confounding	Selection of participants into the study	Classification of interventions	Deviations from intended interventions	Missing data	Measurement of outcomes	Selection of the reported result	Overall bias
Chivapricha, 2021								
Garland, 2021								
Herawati, 2020								
Van der Linden, 2017								

Rob 2

First author, year	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall bias
Alsaad, 2015						
Blum, 2021						
Boersma, 2019						
Bonnerup, 2020						
Cateau, 2021						
Coronado-Vázquez, 2019						
Cossette, 2017						
Dalleur, 2014						
Frankenthal, 2014						
Fried, 2017						
Gallagher, 2011						
O'Connor, 2016						
O'Mahony, 2020						
Price, 2017						

Figure 2. Risk of bias assessment.

intervention demonstrated a more significant decrease in the mean number of regular medications in the exposure group, from 8.96 at the starting point to 6.88 at 12 months, compared with that in the comparison group (from 9.85–8.87) ([DID] 1.1; $p < 0.001$). Additionally, the mean number of medications was significantly decreased when testing all medications²⁰.

Overall, the intervention with STOPP/START screening and PEPS is likely to affect the number of reducing polypharmacy in elderly patients (low evidence quality). Because of high or unclear ROB across multiple domains (–1) and impreciseness because of low event numbers (–1). The evidence was downgraded.

A reduction in the number of drug interactions was analyzed in two studies. One study with STOPP/START screening intervention showed significantly reduced drug-drug interaction in the exposure group at discharge and throughout the monitoring; a reduction was observed in the number of drug-disease interactions from admission to discharge (5% in the comparison group and 11.2% in the exposure group)¹⁶. One study with STRIP intervention showed no significant difference in the reduction of drug-drug interactions within 2 months between the exposure and comparison groups (55.5% vs. 58.3%; $p = 0.31$; odds ratio was 0.87 [0.67–1.14])¹⁷. Meta-analysis of the number of reduced drug interactions within two months investigated as an outcome measure in 2095 elderly patients showed no significant difference between the exposure and comparison groups (odds ratio was 0.84 [0.70–1.02]; $p = 0.08$) with the heterogeneity of $I^2 = 84%$ (Fig. 3A).

Overall, the intervention with STOPP/START screening may influence the reduction in the number of drug interactions; however, STRIP may not affect the reduction in the number of drug interactions in elderly patients (moderate evidence quality). The evidence was downgraded because of heterogeneity in reporting of the outcome (–1).

The number of inappropriate medications was evaluated in ten studies, which showed mixed effects. Eight studies demonstrated a significant number of inappropriate medications or reduction of PIM or *potentially inappropriate prescription* (PIP). One study with STRIP intervention demonstrated significant changes in the number of implemented PIM between the exposure and comparison groups (46.2% vs. 15.3%, $p < 0.005$; odds ratio was 0.14 [0.07–0.57])²¹. One study delivered geriatric pharmacy specialist intervention with pharmaceutical care; it showed a significant decrease in the prevalence of PIM upon discharge from the hospital in the exposure group (21.3% and 43.3%, $p < 0.05$); additionally, the number of PIM was lesser in the exposure group than in the comparison group (21.3% vs. 40.9%, $p = 0.036$). However, no significant difference in prevalence on admission was observed when compared to that during hospitalization in either group²². One study with Intervention Inpatient Geriatric Consultation Team (IGCT) using STOPP criteria recommendations showed a significant reduction in PIM discontinued at hospital admission compared with that at discharge in the exposure and comparison groups (39.7% vs. 19.3%; $p = 0.013$; odds ratio was 2.75 [1.22–26.24]), but no significant




Figure 3. (a) “Meta-analysis” of the effect of interventions on A: number of reducing drug interactions within 2 months; (b) number of potential prescription omission (PPO).

subtraction at the patient level for the prevalence of PIM among the exposure and comparison group (23.1% vs. 16.1%; $p = 0.454$; odds ratio was 1.5 [0.49–4.89])²³. One study with STOPP/START screening intervention showed a significant reduction in PIPs in the exposure group at six months of monitoring ($p < 0.001$) and during 6 to 12 months of monitoring ($p < 0.001$) compared to that at the starting point¹⁵. One study with TRIM intervention showed that the number of medication reconciliation faults was significantly higher in the exposure group than in the comparison group (48.4% vs. 14.3%; $p < 0.001$)¹². One study with PEPs model medication ($p = 0.002$) and all medications (regular and as needed) ($p < 0.001$) between the exposure and comparison groups showed a significant reduction, but no significant prevalence ≥ 1 PIM in regular medication ($p = 0.37$) and all medication ($p = 0.12$)²⁰. One study with pharmacist intervention showed a significant difference in PIMs identified by RASP between the exposure and comparison groups (median [IQR] 0.5 [0–1] vs. 2 [1–3]; $p < 0.001$)¹⁹. One study with shared-decision-making intervention reported a significant difference in the mean number of inappropriate medications withdrawn post-monitoring between the exposure and comparison groups (mean difference was 0.34 [0.01–0.66]; $p = 0.04$); however, no significant difference was observed in the group of respondents whose medication was altered after 6 months of monitoring (odds ratio was 2.8 [1.3–6.1]; $p = 0.008$)²⁴. Two studies showed no significant difference in the number of inappropriate medications related to PIM or PIP. One study with QC-Mode intervention showed no significant difference in the number of PIM galenic units (regression coefficient was $-0.014[-0.038 + 0.010]$; $p = 0.240$) and reduction in the number of PIM defined daily dose resident (regression coefficient was $-0.183[-0.392; +0.025]$; $p = 0.083$) between the exposure and comparison groups¹¹. One study with STOPP-guideline-based intervention showed no significant alteration in the PIP rate between the exposure and comparison groups ($p = 0.80$)¹⁴.

Overall, most of the interventions affected the number of inappropriate medications; only a few showed no effect (very low evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (-1), heterogeneity in reporting of the outcome (-1), and imprecision because of low event numbers (-1).

The number of potential prescription omissions was observed in four studies, all related to prescribing. Three studies showed a significant reduction in potential prescribing omissions (PPOs). Two studies with STOPP/START screening intervention showed a significant reduction in PPOs. One of these studies showed a significant reduction in the exposure group at six months of monitoring ($p < 0.001$) but no significant reduction during 6 to 12 months of monitoring ($p > 0.99$); nevertheless, the prevalence of PPOs tended to drop. This study also showed a significant number of PPOs among the two groups at 12 months of monitoring ($p < 0.001$)¹⁵. Another study demonstrated a reduction in the incidence of incorrectly prescribed doses in the exposure group at discharge, the prevalence of prescribing omissions, and under-prescribing (1.2%; 31.6%; 31.4%)¹⁶. One study with STRIP intervention showed a significant difference in the number of implemented PPO between the exposure and comparison groups (26.2% vs. 3.4%; $p < 0.001$); however, the difference in the number of doses is not significant between the exposure and comparison groups (4.6% vs. 0.0%; $p = 0.1$) because of suboptimal dosage²¹. One study with stratified medication review intervention showed no significant difference in the number of prescribing errors between the exposure and comparison groups, based on events per patient (mean was 0.88 [0.67–1.09] vs. 0.84 [0.67–1.01]; $p = 0.86$) and events per drug (mean was 0.11 [0.08–0.14] vs. 0.13 [0.09–0.16]; $p = 0.65$); the significantly greater number of prescribing errors were discovered in the high-risk group⁹. Meta-analysis of the number of potential prescription omissions investigated as an outcome measure in 1210 elderly patients indicated

a significant difference between the exposure group and comparison group (odds ratio was 0.50 [0.37–0.69]; $p < 0.0001$) with the heterogeneity of $I^2 = 94\%$ (Fig. 3B).

Overall, the intervention with STOPP/START screening and STRIP may affect the number of potential prescription omissions in elderly patients (very low evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (–1), heterogeneity in reporting of the outcome (–1), and imprecision because the confidence interval includes the potential for significant harm or benefit (–1).

The number of ADRs identified was determined in eleven studies, which appeared to exhibit a mixed impact. Eight studies indicated no significant difference in the number of identified ADRs related to its general incidence, falls, rehospitalization, and mortality because of ADR. Two studies with STOPP/START intervention showed no significant difference between the exposure and comparison groups with respect to the frequency of hospital readmissions over 6 months of monitoring (67 vs. 64; $p = 0.691$)¹⁶, mean number of hospitalizations ($p = 0.10$), and mean number of falls ($p = 0.28$)¹⁵. Two studies with STRIP intervention showed no significant difference between the exposure and comparison groups with respect to mortality (13.1% vs. 12.1%; $p = 0.859$ ²¹ and 4.3% vs. 5.2%; $p = 0.38$; hazard ratio was 0.81 [0.51–1.29]) and first drug-related hospital admission (21.9% vs. 22.4%; $p = 0.62$; hazard ratio was 0.95 [0.77–1.17])¹⁷. One study with QC-Mode intervention showed no significant difference in the number of falls ($p = 0.575$) and mortality ($p = 0.06$)¹¹. One study with CAS-based pharmacist–physician intervention showed no significant difference in readmissions at 30 days post-discharge (15.9% vs. 21.9%; $p = 0.3$)¹⁸. One study with SENATOR intervention showed no significant difference in ADR incidence between the exposure and comparison groups at the primary endpoint (24.5% vs. 24.8%; odds ratio was 0.98 [0.77–1.24]; $p = 0.88$), at the secondary endpoint (S1) (33.7% vs. 36.7%; odds ratio was 0.87 [0.70–1.08]; $p = 0.20$), (S2) (21.2% vs. 22.9%; odds ratio was 0.91 [0.71–1.15]; $p = 0.42$), and post-hoc; additionally, no significant difference was observed for rehospitalization rate (36.2% vs. 34.9%; odds ratio was 1.05 [0.84–1.32]; $p = 0.66$)²⁵. One study with pharmacy intervention announced no significant difference between the exposure and comparison groups with respect to mortality ($p = 1.000$; $p = 1.000$) and number of falls ($p = 0.742$; $p = 0.954$) during hospitalization and after discharge and with respect to rehospitalization after discharge ($p = 0.629$)¹⁹. Three studies showed a significant number of identified ADRs related to general ADR/ADE incidence, GerontoNet score, rehospitalization, and mortality. Two studies with STOPP/START intervention showed a significant difference in the incidence of ADR or ADE between the exposure and comparison groups (11.7% vs. 21.0%; odds ratio was 0.50 [0.33–0.75]; $p = 0.001$ ²⁶ and 3 vs. 13; $p = 0.017$ ²⁷) and for GerontoNet score at the time of step outside (mean = 3.3(2.3) vs. 5.2(2.1); $p = 0.003$)²⁷. One study with comprehensive clinical pharmacist intervention showed a significant difference in the number of identified rehospitalizations (mean was 1.15 [1.01–1.32]) and mortality rate (mean was 0.40 [0.33–0.48])¹⁰.

Overall, most of the interventions may not affect the number of identified ADRs; only a few showed any effect (low evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (–1) and heterogeneity in reporting of the outcome (–1).

Secondary outcomes. *MAI score* was announced in two studies with STOPP/START screening exposure and appeared to be significantly different between the exposure and comparison groups following discharge (mean 2.97(2.25) vs. 9.94(6.14); $p < 0.001$)¹³; the scores decreased from 10 (3–16.25) upon admission to 3 (1–6) at the time of discharge ($T = 447$, $P < 0.001$, $r = -0.52$) and continued to decrease throughout the monitoring period ($X^2_F = 226.312$, $P < 0.001$)¹⁶.

Overall, the intervention with STOPP/START screening is likely to affect MAI scores in elderly patients (moderate evidence quality). Because of the low event numbers, the evidence was downgraded because of imprecision (–1).

AOU was announced in one study. The number required to identify with STOPP/START criteria to give a betterment in the AOU at the time of hospital step outside for the exposure group was 4.7 (3.4–7.5)¹⁶.

Overall, the STOPP/START screening intervention may affect AOU in elderly patients (moderate evidence quality). The evidence was downgraded because of the imprecision (–1) of the low event numbers.

Mortality (all-cause) was determined in three studies; no significant difference was observed between the exposure and comparison groups. One study with STRIP intervention showed no significant difference in mortality between the exposure and comparison groups (19.4% vs. 17.9%; hazard ratio was 0.90 [0.7–1.13]; $p = 0.37$)¹⁷. In one study with STOPP/START screening intervention, the prevalence of mortality attributed to any cause was less in the exposure group than in the comparison group over the 6-month monitoring period; nevertheless, the difference was not significant (5.3% vs. 7.3%; $p = 0.414$)¹⁶. One study with SENATOR intervention showed no significant mortality rate within 30 days between the exposure and comparison groups (7.2% vs. 7.1%; odds ratio was 1.05 [0.70–1.57]; $p = 0.81$)²⁵. Meta-analysis of the number of potential prescription omissions investigated as an outcome measure in 3927 elderly patients indicated no significant difference between the exposure and comparison groups (odds ratio was 0.92 [0.76–1.12]; $p = 0.41$) with the heterogeneity of $I^2 = 0\%$ (Fig. 4).

Overall, the STRIP, STOPP/START screening, and SENATOR interventions are likely to reduce mortality (all causes) in elderly patients (moderate evidence quality). The evidence was downgraded because of inconsistency with the confidence interval, which includes the possibility of significant critical harm or benefit (–1).

Length of Stay was determined in five studies. Two studies with STOPP/START screening intervention showed no significant difference in the duration of stay between the exposure and comparison groups (median [IQR] 8 [5–14] vs. 8.5 [5–15.75], $p = 0.471$)¹⁶; median [IQR] 8 [4–14] vs. 8 [4–14]). The median length of stay was significantly longer among respondents who developed ADR relative to those who did not (median [IQR] 10 [6–14, 17, 19, 20] vs. 7 [4–14]; $p < 0.001$)²⁶. One study with CAS-based pharmacist–physician intervention showed no significant difference in length of stay between the exposure and comparison groups (median [IQR] 10 [6–14, 17, 19, 20, 25, 27] vs. 9.5 [5–14, 17, 19, 20, 24, 25, 27, 30]; $p = 0.9$)¹⁸. One study with SENATOR intervention showed no significant difference in length of stay between the exposure and comparison groups (median [IQR] 6 [3–10])




Figure 4. A “meta-analysis” of the effect of interventions on mortality (all-cause).

vs. 6 [3–11])²⁵. One study with STOPP/START screening intervention showed a significant difference in length of stay between the exposure and comparison groups (mean 7.6 [3,0] vs. 14.2 [10,0]; $p = 0.011$)¹³.

Overall, most of the interventions may not affect the length of stay; only a few showed any effect (very low evidence quality). The evidence was downgraded because of high or unclear ROB across multiple domains (–2) and impreciseness because of low event numbers (–1).

Quality of Life was determined in five studies. Four studies with EQ-5D-3L measurement showed no significant difference in the quality of life between the exposure and comparison groups (0.358[SD 0.016] vs. 0.294 [SD 0.018])¹⁹ at day 90 of the monitoring period ($p = 0.73$) compared with that at the initiation of monitoring ($p = 0.65$)⁹; the quality of life was not significantly different after discharge compared with that at the starting point for both groups (DM was 0.14[0.11–0.18]; $p < 0.001$). However, no significant difference was observed in the quality of life at discharge and at the starting point between the exposure and comparison groups (DM[95%CI] = –0.02[–0.10–0.06]; $p = 0.5942$)²⁵. Significantly superior quality of life was observed after one year in the exposure group compared to that in the comparison group (17.8% vs. 19.1%; mean difference was 2.29[0.31–4.26]; $p = 0.02$)¹⁷. One study with an SF-12 questionnaire showed no significant difference in the quality of life between the exposure and comparison groups with respect to the mean scores for the physical ($p = 0.09$) and mental components ($p = 0.70$) after one year of monitoring¹⁵.

Overall, the interventions may have little or no impact on the quality of life in elderly patients (moderate evidence quality). The evidence was downgraded because of heterogeneity in reporting of the outcome (–1).

Discussion

Eighteen studies included in this systematic review provided significantly varying results, according to the synthesis of quantitative analysis of their outcomes and meta-analysis suitable only for three outcomes in this review. Previous systematic reviews have evaluated screening tools used by clinical pharmacists for the identification of drug-related problems among elderly patients²⁷. In this study, we included all tools utilized by the health workers for detecting ADR, and this is the first study to perform such an evaluation using the indicated criteria. We additionally provide a synthesis of narratives from the findings. The interventions targeted over 8000 elderly individuals; however, the exact number of elderly individuals was poorly reported in two studies^{11,14}. Most of the trials were conducted in hospitals; however, some were conducted in clinics and homes for the elderly. Currently, the output of this systematic review cannot support the use of any instrument or tool intended to predict or detect ADR for the prevention and reduction of ADR. Only three studies demonstrated the prediction or prevention of ADR using STOPP/START screening and STRIP as an instrument; however, the results are not significant. Nevertheless, STOPP/START resulted in a lower prevalence of ADR in the exposure group than in the comparison group (5.8% vs. 8.4%; $p = 0.332$)¹⁶. Most of the instruments such as STOPP/START successfully identified ADR related to general ADR/ADE incidence, GerontoNet score, rehospitalization, and mortality. The results for the exposure and comparison groups (11.7% vs. 21.0%; odds ratio was 0.50 [0.33–0.75]; $p = 0.001$)²⁶ and 3 vs. 13; $p = 0.017$)²⁷ and GerontoNet score at the time of step outside (mean = 3.3(2.3) vs. 5.2(2.1); $p = 0.003$)²⁷. Furthermore, comprehensive clinical pharmacist intervention also successfully identified the number of rehospitalizations (mean was 1.15 [1.01–1.32]) and the mortality rate (mean was 0.40 [0.33–0.48])¹⁰. Most of the instruments successfully identified the number of inappropriate medications and reduction of PIM or PIP. The STRIP intervention successfully changed the number of implemented PIM between the exposure and comparison groups (46.2% vs. 15.3%, $p < 0.005$; odds ratio was 0.14 [0.07–0.57])²¹. The geriatric pharmacy specialist intervention with pharmaceutical care also decreased the prevalence of PIM upon discharge from the hospital in the exposure group (21.3% and 43.3%, $p < 0.05$); additionally, the number of PIM was lesser in the exposure relative to the comparison group (21.3% vs. 40.9%, $p = 0.036$)²². The START/STOPP criteria successfully reduced the PIM discontinuation at hospital admission relative to that at discharge between the exposure and comparison groups (39.7% vs. 19.3%; $p = 0.013$; odds ratio was 2.75 [1.22–26.24])²³. Reduction in PIPs in the exposure group at six months of monitoring ($p < 0.001$) and during 6 to 12 months of monitoring ($p < 0.001$) as compared to that at the starting point was recorded¹⁵. The TRIM intervention showed that the number of medication reconciliation faults was higher in the exposure group than in the comparison group (48.4% vs. 14.3%; $p < 0.001$)¹². Reduced PIM results in a decrease in the PEPS model ($p = 0.002$) and all medications (regular and as needed) ($p < 0.001$) between the exposure and comparison groups²⁰. The pharmacist intervention successfully identified PIMs by RASP between the exposure and comparison groups (median [IQR] 0.5 [0–1] vs. 2 [1–3]; $p < 0.001$)¹⁹. The shared-decision-making intervention also exhibited a difference in the mean number of inappropriate medications withdrawn post-monitoring between the exposure and comparison groups (mean difference was 0.34 [0.01–0.66]; $p = 0.04$)²⁴. However, they were associated with low- or very low-quality evidence, which implies that we cannot

recommend any of the currently published instruments for predicting or detecting ADR in elderly patients. A previous systematic review also evaluated the interventions based on health outcomes in reducing the incidence of ADEs in elderly patients in primary care settings, but the results of the interventions showed no significant benefit in terms of health outcomes such as hospitalization, emergency department visits, mortality, and quality of life. The intervention of prescription or review of medications by health workers was the most commonly used approach by the pharmacists²⁸.

Our meta-analysis identified that the interventions affect the number of PPOs; however, heterogeneity was high among the included studies. This heterogeneity could be attributed to variability in the interventions and methodological diversity. However, our findings must be interpreted with caution. Although a substantial number of studies were included in this review, there remains the need for further high-quality evidence for an instrument that adequately predicts or detects ADR. None of the studies included in this review provided external validation that affords conviction that a particular instrument's prognostic capability is credible across different populations and settings.

Limitations

This systematic review has several possible limitations. The search strategies for identifying relevant studies included the use of "adverse drug reaction prediction and/or detection instruments" as a fundamental term of search. While this was expected to be applicable because the systematic review aimed to prioritize patients subjected to adverse drug reaction prediction and/or detection instruments, other research that predicted or detected ADR in the elderly could have been excluded if the study methodology did not include instruments or tools. We used the PICOT framework to establish the search strategy, to reduce the possibility of "missing" related studies, and all four researchers thoroughly discussed the search terms to be used. Furthermore, language was also a limitation in the selection of included studies. It was difficult to conduct a meta-analysis for some studies, considering the type of methodologies and patient demographics, the outcomes, and the reporting of outputs. Another limitation is that some of the studies included in the meta-analysis exhibited significant statistical heterogeneity. Thus, the pooled effect estimates should be interpreted with caution. This variation could be attributed to intervention variability and methodological diversity. Therefore, future research should strive for greater agreement on defining and assessing preventability to reduce heterogeneity among studies and allow more precise estimates for future meta-analyses.

According to the findings of this systematic review, many tools have been developed for use in hospitals, clinics, and homes for the elderly for the prediction or detection of ADR in elderly patients. The complexity of the tools developed to date and the outcome measures and methods used for validating their performance vary. There is no definitive validated assessment tool for widespread use in older patients. The findings reveal that most instruments evaluated could identify ADR and inappropriate medications.

Conclusion

According to the findings of this systematic review, many tools have been developed for use in hospitals, clinics, and homes for the prediction or detection of ADR in elderly patients. The complexity of the tools developed to date and the outcome measures and methods used for validating their performance vary substantially. There is no definitive validated assessment tool for widespread use for older patients. The findings reveal that most instruments evaluated could identify ADR and inappropriate medications.

Methods

Data sources and study selection. The authors developed a systematic search strategy. The database search was performed until 1 January 2022 without the application of date restrictions: EMBASE, MEDLINE (Ovid), CINAHL, Pubmed, Web of Science, and ProQuest.

The reviewers filtered all article titles based on the PICOT search strategy and tailored them to each database with no restrictions. Key search terms consisted of three main concepts: elderly with morbidity, adverse drug reaction prediction and/or detection instruments, polypharmacy, and an in-depth list of synonyms, given the variable terminology in the field.

If possible, the terminology of Medical Subject Headings was used (in OVID, EMBASE, and MEDLINE); for databases not using the terminology of Medical Subject Headings, keywords were used (CINAHL, Pubmed, Web of Science, and ProQuest). The search strategy was developed by the authors in collaboration with an experienced librarian. The complete details of the search strategies have been provided in the supplementary material.

We used the Endnote and Rayyan programs to classify the results and excluded the same articles²⁹. The review of titles and screening of the article abstracts used in this study were performed by two independent reviewers. The previous stage involved screening of the full-text review of the article by two independent reviewers; if an agreement was not reached, a third reviewer was consulted. Each search stage records all exclusion criteria for creating a flow diagram as stated by the components heeled in "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA)^{30,31}. The selection process is repeated independently for both purposes.

Inclusion criteria. In this review, we included CCT- or RCT-based original research/studies published in English and Indonesian that enrolled elderly patients (≥ 60 years old) with morbidity and polypharmacy as respondents, and hospitals, homes for elderly individuals, and communities with public and private healthcare systems as research settings.

Exclusion criteria. We excluded the following studies from the review: literature reviews, systematic reviews, meta-analyses, discussion articles, conference proceedings, summary articles, editorials, studies on

patients with COVID-19, and studies investigating specific parameters (e.g., HbA1c control, blood glucose, or dementia) that did not involve elderly patients (≥ 60 years). Additionally, we excluded research protocols whose results had not been published or were not available in the database and for which only abstracts were available for analysis.

Data extraction, synthesis, and analysis. The full text was assessed independently by two reviewers (DA and EZ), and data were extracted. The data extraction forms were designed considering the study's two objectives, and the data was entered into tables in the Excel software. We pulled all research articles that present the use of an instrument for predicting and/or detecting ADR in elderly patients, based on the first objective. Subsequently, based on the second objective, we extracted all research articles that present the evaluation results of using an instrument for predicting and/or detecting ADR in elderly patients, as indicated by the number of predicted and prevented ADR or *adverse events* (AE), polypharmacy, drug interactions, number of inappropriate medications, and number of potential prescription omissions (PPO).

“RoB 2 and ROBINS-I” were handled as tools for appraising the risk of bias^{32,33}. RoB 2 is used for RCT studies and ROBINS-I for CCT studies. To appraise the evidence quality, we used GRADE, and two researchers conducted all of these procedures to validate the obtained data³⁴.

The reviewers performed data analyses using the Review Manager (RevMan) software³⁵, version 5.4 after data extraction based on the objectives of this systematic review. The odds ratios (OR) for dichotomous outcomes were calculated alongside the 95% confidence intervals (CIs). To determine the heterogeneity of the studies, I^2 was calculated. The summary of grouped data included research methods, population characteristics, settings, and research outcomes. We studied these results in depth to draw conclusions that answer the research question posed in this systematic review.

The protocol of this systematic review is registered in PROSPERO (CRD42021240621).

Data availability

All data generated or analyzed during this study are included in this published article.

Received: 13 April 2022; Accepted: 25 July 2022

Published online: 01 August 2022

References

- (EMA) EMA. Guideline on good pharmacovigilance practices (GVP). Definition. 2017(United Kingdom): Annex I.
- Food and Drug Administration Department of Health and Human Services, Chapter I. United States and America. Subchapter D—Drugs for human use. FDA. In: FDA; 2018.
- Barclay, K., Frassetto, A., Robb, J. & Mandel, E. D. Polypharmacy in the elderly: How to reduce adverse drug events. *Clin. Rev.* **28**, 38–44 (2018).
- Andersen, L. V., Poulsen, B. K., Poulsen, M. H. & Krogh, M. L. Major drug interactions. In *The ESC Handbook on Cardiovascular Pharmacotherapy* 2nd edn 387–410 (Oxford University Press, 2019).
- Schoenmakers, T. W., Teichert, M., Wensing, M. & de Smet, P. A. Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews: A cross-sectional observational study. *Drug Saf.* **40**, 419–430. <https://doi.org/10.1007/s40264-017-0504-7> (2017).
- Laatikainen, O. *et al.* Hospitalizations due to adverse drug events in the elderly—A retrospective register study. *Front. Pharmacol.* **7**, 358. <https://doi.org/10.3389/fphar.2016.00358> (2016).
- Sakiris, M. A., Sawan, M., Hilmer, S. N., Awadalla, R. & Gnjidic, D. Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review. *Br. J. Clin. Pharmacol.* **87**, 375–385. <https://doi.org/10.1111/bcp.14417> (2021).
- Stevenson, J. M. *et al.* Predicting adverse drug reactions in older adults: A systematic review of the risk prediction models. *Clin. Interv. Aging.* **9**, 1581–1593. <https://doi.org/10.2147/CIA.S65475> (2014).
- Bonnerup, D. K. *et al.* Effects of stratified medication review in high-risk patients at admission to hospital: A randomised controlled trial. *Ther. Adv. Drug Saf.* **11**, 2042098620957142. <https://doi.org/10.1177/2042098620957142> (2020).
- Alassaad, A. *et al.* A tool for prediction of risk of rehospitalisation and mortality in the hospitalised elderly: Secondary analysis of clinical trial data. *BMJ Open* **5**, e007259. <https://doi.org/10.1136/bmjopen-2014-007259> (2015).
- Cateau, D., Ballabeni, P. & Niquille, A. Effects of an interprofessional Quality Circle-Deprescribing Module (QC-DeMo) in Swiss nursing homes: A randomised controlled trial. *BMC Geriatr.* **21**, 289. <https://doi.org/10.1186/s12877-021-02220-y> (2021).
- Fried, T. R. *et al.* Effect of the tool to reduce inappropriate medications on medication communication and deprescribing. *J. Am. Geriatr. Soc.* **65**, 2265–2271. <https://doi.org/10.1111/jgs.15042> (2017).
- Herawati, F., Maharjana, I. B. N., Kuswardhani, T. & Susilo, A. P. STOPP-START medication review: A non-randomized trial in an Indonesian tertiary hospital to improve medication appropriateness and to reduce the length of stay of older adults. *Hosp. Pharm.* **56**, 668–677. <https://doi.org/10.1177/0018578720942227> (2021).
- Price, M., Davies, I., Rusk, R., Lesperance, M. & Weber, J. Applying STOPP guidelines in primary care through electronic medical record decision support: Randomized control trial highlighting the importance of data quality. *JMIR Med. Inform.* **5**, e15. <https://doi.org/10.2196/medinform.6226> (2017).
- Frankenthal, D., Lerman, Y., Kalendaryev, E. & Lerman, Y. Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: A randomized clinical trial. *J. Am. Geriatr. Soc.* **62**, 1658–1665. <https://doi.org/10.1111/jgs.12993> (2014).
- Gallagher, P. F., O'Connor, M. N. & O'Mahony, D. Prevention of potentially inappropriate prescribing for elderly patients: A randomized controlled trial using STOPP/START criteria. *Clin. Pharmacol. Ther.* **89**, 845–854. <https://doi.org/10.1038/clpt.2011.44> (2011).
- Blum, M. R. *et al.* Optimizing Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older Adults (OPERAM): Cluster randomised controlled trial. *BMJ* **374**, n1585. <https://doi.org/10.1136/bmj.n1585> (2021).
- Cossette, B. *et al.* Reduction in targeted potentially inappropriate medication use in elderly inpatients: A pragmatic randomized controlled trial. *Eur J Clin Pharmacol.* **73**, 1237–1245. <https://doi.org/10.1007/s00228-017-2293-4> (2017).
- Van der Linden, L. *et al.* Combined use of the rationalization of home medication by an adjusted STOPP in older patients (RASP) list and a pharmacist-led medication review in very old inpatients: Impact on quality of prescribing and clinical outcome. *Drugs Aging.* **34**, 123–133. <https://doi.org/10.1007/s40266-016-0424-8> (2017).

20. Garland, C. T. *et al.* A new care model reduces polypharmacy and potentially inappropriate medications in long-term care. *J. Am. Med. Dir. Assoc.* **22**, 141–147. <https://doi.org/10.1016/j.jamda.2020.09.039> (2021).
21. Boersma, M. N. *et al.* The effect of providing prescribing recommendations on appropriate prescribing: A cluster-randomized controlled trial in older adults in a preoperative setting. *Br. J. Clin. Pharmacol.* **85**, 1974–1983. <https://doi.org/10.1111/bcp.13987> (2019).
22. Chivapricha, W., Srinonprasert, V. & Suansanae, T. Impact of geriatric pharmacy specialist interventions to reduce potentially inappropriate medication among hospitalized elderly patients at medical wards: A prospective quasi-experimental study. *Drugs Real World Outcomes.* **8**, 39–47. <https://doi.org/10.1007/s40801-020-00214-7> (2021).
23. Dalleur, O. *et al.* Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: A randomised controlled study. *Drugs Aging.* **31**, 291–298. <https://doi.org/10.1007/s40266-014-0157-5> (2014).
24. Coronado-Vázquez, V. *et al.* Shared decision-making in chronic patients with polypharmacy: An interventional study for assessing medication appropriateness. *J. Clin. Med.* **8**, 904 (2019).
25. O'Mahony, D. *et al.* Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: The SENATOR* randomized controlled clinical trial. *Age Ageing.* **49**, 605–614. <https://doi.org/10.1093/ageing/afaa072> (2020).
26. O'Connor, M. N. *et al.* Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons' prescriptions and screening tool to alert to right treatment criteria: A cluster randomized controlled trial. *J. Am. Geriatr. Soc.* **64**, 1558–1566. <https://doi.org/10.1111/jgs.14312> (2016).
27. Brady, A., Curtis, C. E. & Jalal, Z. Screening tools used by clinical pharmacists to identify elderly patients at risk of drug-related problems on hospital admission: A systematic review. *Pharmacy.* <https://doi.org/10.3390/pharmacy8020064> (2020).
28. Tecklenborg, S., Byrne, C., Cahir, C., Brown, L. & Bennett, K. Interventions to reduce adverse drug event-related outcomes in older adults: A systematic review and meta-analysis. *Drugs Aging.* **37**, 91–98. <https://doi.org/10.1007/s40266-019-00738-w> (2020).
29. Ouzzani, M., Hammady, H., Fedorowicz, Z. & Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. *Syst. Rev.* **5**, 210. <https://doi.org/10.1186/s13643-016-0384-4> (2016).
30. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ.* **339**, 2535 (2009).
31. Salameh, J. P. *et al.* Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist. *BMJ* **370**, m2632. <https://doi.org/10.1136/bmj.m2632> (2020).
32. Sterne, J. A. *et al.* Robins-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **355**, i4919. <https://doi.org/10.1136/bmj.i4919> (2016).
33. Sterne, J. A. C. *et al.* RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **366**, l4898. <https://doi.org/10.1136/bmj.l4898> (2019).
34. Guyatt, G. *et al.* GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J. Clin. Epidemiol.* **64**(4), 383–394. <https://doi.org/10.1016/j.jclinepi.2010.04.026> (2011).
35. Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020.

Acknowledgements

The authors would like to thank The Ministry of Research, Technology and Higher Education of Indonesia for providing grants for implementing this research.

Author contributions

D.S.A. and E.Z. conceptualized the study, had full access to all data analyzed in the study, and took responsibility for the integrity of the data and the accuracy of data analysis. All authors contributed to the study's conception and design. S.H., Y.L., and E.Z. supervised the study. The first draft of the manuscript was written by D.S.A., and all authors commented on previous versions of the manuscript. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Funding

This research was supported by The Ministry of Research, Technology and Higher Education of Indonesia (a doctoral dissertation grant- PDD 2021).

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-17410-w>.

Correspondence and requests for materials should be addressed to E.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2022

Scientific Reports

COUNTRY

[United Kingdom](#)

 Universities and research institutions in United Kingdom

 Media Ranking in United Kingdom

SUBJECT AREA AND CATEGORY

[Multidisciplinary](#)
[Multidisciplinary](#)

PUBLISHER

[Nature Publishing Group](#)

H-INDEX

242

PUBLICATION TYPE

[Journals](#)

ISSN

20452322

COVERAGE


2011-2021

INFORMATION

[Homepage](#)
[How to publish in this journal](#)
scientificreports@nature.com

SCOPE


We publish original research from all areas of the natural and clinical sciences. You can learn more about what we publish by browsing our specific scientific subject areas below, or exploring Scientific Reports by browsing all articles and collections.

 [Join the conversation about this journal](#)

FIND SIMILAR JOURNALS ?

options ⌵

- 1
Journal of Biosciences
- 2
International Journal of
- 3
Advances in Experimental
- 4
Journal of Visualized
- 5
PLoS ONE



Scientific Reports

← Show this widget in your own website

Just copy the code below and paste within your html code:

`https://www.scimagojr.com`

powered by scimagojr.com

SCImago Graphica

Explore, visually communicate and make sense of data with our [new data visualization tool](#).

Metrics based on Scopus® data as of April 2022

M Mohamed Reza Sazideh 3 months ago

I could publish my article in this journal. It is very good one

reply

Melanie Ortiz 3 months ago

Dear Mohamed, thanks for your participation! Best Regards, SCImago Team

G gholamreza 12 months ago

Dear Editor,

Could you please tell me whether publication in the scientific reports Journal is free of charge or

not?

Best wishes,

G. Khayatian

reply



Melanie Ortiz 12 months ago

SCImago Team

Dear Gholamreza,
Thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
We suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

A **Alex Egorov** 2 years ago

It seems that there's an error with 2011 citations per paper, that's why 2012 3-year impact calculated was 2 and something. It would greatly improve your statistics if you could fix that bug

reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Alex,
Thank you for contacting us.
As you probably already know, SCImago calculates the scientometric indicators based on the data sent by Scopus. Keep in mind that these data are a static image of Scopus database and that this one increases its documents daily. Besides, data are now only calculated for the last year that has entered the database.
Best Regards, SCImago Team

A **Abouzar** 3 years ago

Hi, Does it include review articles?

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Abouzar,
thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

H **Hamid** 3 years ago

Dear publisher,
Is it possible to submit our research, which includes experimental and theoretical material comparisons?
The theory has been done using the DFT.

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Hamid,

Thank you for contacting us. Please see comments below.

Best Regards, SCImago Team

N **Napaporn Kuamsab** 3 years ago

good

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Napaporn, thanks for your participation! Best Regards, SCImago Team

M **M.C.AKGUNDUZ** 3 years ago

An article that was previously published in Sci. Rep.(<https://doi.org/10.1038/s41598-020-58170-9>). Although the article was published in January 2020, it does not appear in web of science. I wonder if the articles in Scientific reports are not indexed in web of science?

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Sir/Madam,
thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
Unfortunately, we cannot help you with your request.
Best Regards, SCImago Team

W **Walaa Sayed** 3 years ago

Good morning
Thank you ever so much if you help me to know if the scientific reports journal is indexed on Thomson Reuters or not?

Best regards

reply

M **Manal Fawzy** 3 years ago

Hi Walaa
Sure it is indexed in Thomson Reuters and an easy way to know if the journal you have a query about indexed or not is to follow this link"

<https://mjl.clarivate.com/home>

Copy and paste the journal name in the box to ensure the precise journal name and if the journal indexed in web of science (previously called Thomson Reuters), it will appear for you with some details regards the publisher and the journal online link.

good Luck



Melanie Ortiz 3 years ago

SCImago Team

Dear Manal, thanks for your participation! Best Regards, SCImago Team



Melanie Ortiz 3 years ago

SCImago Team

Dear Walaa,
Thank you for contacting us. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus. Unfortunately, we cannot help you with your request referring the index status. We suggest you to consult Scopus database (see the current status of the journal) or other databases (like WoS) for further information. You can also check that information in the journal's website or contact directly with the editorial staff. Best Regards, SCImago Team

O **Orass M.** 3 years ago

Dear Editor
Can you help me if publishing free for scientific research in your journal or not.
with many thanks

reply

N **Nadia Boutabba** 10 months ago

Scientific reports, have charges for the publications, you can see this on their website



Melanie Ortiz 3 years ago

SCImago Team

Dear Orass,
thank you for contacting us.
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.
Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.
Best Regards, SCImago Team

M **mozhdeh** 3 years ago

Unfortunately, I have not been able to find the answer to my question and intend to publish my article in the field of asthma in this journal, but I do not know how long it will take for the final decision to be accepted or rejected.

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Mozhed,
thank you for contacting us.

We suggest you to contact the journal's editorial staff , so they could inform you more deeply. Best Regards, SCImago Team

M **mozhdeh dalouchi** 3 years ago

Dear editor

May i know how long first decision takes to accept or reject of article mostly?

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Mozhed,

thank you for contacting us.

We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.

Unfortunately, we cannot help you with your request, we suggest you to visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.

Best Regards, SCImago Team

R **ritika** 3 years ago

I have a review article on binaural beats. what is the possibility of review article in this journal

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Ritika,

thank you for contacting us.

We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.

Unfortunately, we cannot help you with your request, we suggest you to contact the journal's editorial staff , so they could inform you more deeply. Best Regards, SCImago Team

Team

S **samira zareei** 3 years ago

dear editor

i have a paper with bacteriophage isolation, can i submit it at you journal?

thank you

reply



Melanie Ortiz 3 years ago

SCImago Team

Dear Samira, thank you very much for your comment, we suggest you to look for author's instructions/submission guidelines in the journal's website. Best Regards, SCImago Team

E **Emil Boros** 4 years ago

Dear SCImago Team,

I've read an interesting paper in your journal, and it is possible that I could take some interesting comments with more details by my experiments and data for better discussion and conclusions. The comment type of short paper is common at several journal. Is it possible at your journal and how?

Thank you!

best regards,

reply

I **issac** 4 years ago

may i know how long the acceptance takes mostly?

reply

B **Borhanm** 3 years ago

Almost 4-5 months

S **Sadegh** 4 years ago

Dear friend

It is difficult to answer to this question.

It depends on the subject of your paper and even the editor and those person invited as referees, my personal experience, it takes one year!

**Elena Corera** 4 years ago

SCImago Team

Thank you very much for the information!

Best regards,
SCImago Team**Elena Corera** 4 years ago

SCImago Team

Dear Issac,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you look for author's instructions in the journal's website.
Best Regards,
SCImago Team**D Dr.Thittauwadee Intarangkul** 4 years agoเรียน ผู้จัดการหนังสือ
ดิฉันประสงค์ลงงานวิจัยในวารสารของท่าน ขอความกรุณาตอบรับงานวิจัยของฉัน ขอบคุณ

reply

**Elena Corera** 4 years ago

SCImago Team

Dear user,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you look for author's instructions in the journal's website.
Best Regards,
SCImago Team**M muhamad yunus abdullah** 5 years ago

if I mean it in the journal what percentage can be accepted thanks

reply

M Mohammed Ali 4 years ago

59%

**Elena Corera** 4 years ago

SCImago Team

Thank you very much for participating!

**Elena Corera** 5 years ago

SCImago Team

Dear Muhamad,
thank you very much for your comment, unfortunately we cannot help you with your request. We suggest you look for author's instructions in the journal's website.
Best Regards,
SCImago Team**A ali** 5 years ago

physicist in renewable energies direcorate

reply

A ali 5 years ago

physicist

reply

A ali 5 years ago

physicist

reply

Leave a comment

Name

Email

(will not be published)

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS
Horatio (Satire 1.1, 106)

[Cookie settings](#)

[Cookie policy](#)